Top 5 Penny Stocks To Buy For 2014

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

NEW YORK (TheStreet) -- Where can investors find the best growth stocks? All over place, if you know where to look, Jim Cramer said on "Mad Money" Tuesday.

In the biotech space, Cramer called out Regeneron (REGN) as one such stock -- it has growth today and, thanks to a robust pipeline of new drugs, for many years to come. The oil patch is littered with high-growth stocks, including EOG Resources (EOG), Cramer continued.

Restaurants Red Robin Gourmet Burgers (RRGB) and Starbucks (SBUX) both have growth, as do retailers Michael Kors (KORS), which delivered a 49% increase in profits and a 23% increase in sales this quarter. Cramer said just about any stock that deals with mobile, social media or the cloud is growing like gangbusters -- which leads right to this week's Twitter IPO. Just a few weeks ago, Cramer noted, he was at the high end of the range, saying Twitter could be worth up to $20 billion. But today, despite nothing factually changing, $20 billion seems at the low end of the range, with some calling for valuations as high as $50 billion for Twitter. Cramer said that's a recipe for investors to get hurt, a la the Facebook (FB) IPO last year. He cautioned that the big boys are betting big that uninformed investors will be willing to pay anything for shares of Twitter -- which is why he's once again reminding everyone there are prices at which every stock just becomes uninvestable. Cramer said he's willing to pay up to $28 a share for Twitter and not a penny more. Executive Decision: In the "Executive Decision" segment, Cramer sat down with Dr. Ron Cohen, president and CEO of Acorda Therapeutics (ACOR), a stock that's up 31% so far in 2013 and just delivered a 16-cents-a-share earnings beat. Cohen said sales of Acorda's multiple sclerosis drug, Ampyra, is the engine that's helping to drive the company forward and Acorda is very fortunate to have such a successful product. Acorda is not a one-hit wonder, however, as the company now has six drugs in clinical studies, including new formulations of ingredients of Amypra that may treat strokes and other conditions.

Top Defensive Companies To Buy For 2015: Westinghouse Solar Inc.(WEST)

Westinghouse Solar, Inc. engages in the design, manufacture, integration, and installation of solar power systems under the Westinghouse name. It offers its solar power systems for residential and commercial customers. The company also designs and distributes solar panels with integrated micro inverters (called as AC solar panels). The company sells its AC solar panels to solar installers, trade workers, and do-it-yourself customers through distribution partnerships, dealer network, and retail outlets. It has a strategic partnership with Real Goods Solar, whereby Real Goods Solar operates as an authorized dealer for westinghouse solar power systems for sale to its customers in California and Colorado markets. The company was formerly known as Akeena Solar, Inc. and changed its name to Westinghouse Solar, Inc. on Apr 14, 2011. Westinghouse Solar, Inc. was founded in 2001 and is headquartered in Campbell, California.

Advisors' Opinion:

• [By John Udovich]

  Small cap solar stock Andalay Solar Inc (OTCMKTS: WEST) has largely cratered for investors�verses solar stock peers Real Goods Solar, Inc (NASDAQ: RSOL) and SolarCity Corp (NASDAQ: SCTY), but is the company finally turning itself around after a failed deal to be acquired?

Top 5 Penny Stocks To Buy For 2014: Theravance Inc.(THRX)

Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines for various therapeutic areas, including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. The company?s key development programs with GlaxoSmithKline (GSK) include the RELOVAIR, a Phase 3 clinical trial program for the treatment of patients with chronic obstructive pulmonary disease (COPD) and/or asthma; the LAMA/LABA program, a Phase 3 COPD program; and the Bifunctional Muscarinic Antagonist-beta2 Agonist (MABA) program, a Phase 2b program for the treatment of COPD, as well as Peripherally Selective Mu-Opioid Receptor Antagonist (P Advisors' Opinion:

• [By Sean Williams]

  Finally, Theravance (NASDAQ: THRX  ) made waves after announcing that it would be splitting its business into two separate components: Royalty Management, which will focus on drugs currently in the pipeline in collaboration with GlaxoSmithKline, and Theravance BioPharma, which will continue its line of small-molecule rare disease research. Clearly, this gives investors more visibility of where revenue and profit are coming from, but I think it gives Glaxo even more reason to gobble up the Royalty Management segment because now it doesn't have to buy the remaining pipeline of rare disease research.

• [By Sean Williams]

  A revolutionary COPD treatment?
  On Wednesday, chronic obstructive pulmonary disease, or COPD, treatment collaborators GlaxoSmithKline (NYSE: GSK  ) and Theravance (NASDAQ: THRX  ) are set to go before the FDA's panel with their combo Breo Ellipta. This revolutionary drug combines Theravance's long-acting beta-2 agonists with Glaxo's long-acting muscarinic antagonists into a dry powder inhaler to provide long-term COPD relief.

Top 5 Penny Stocks To Buy For 2014: L-3 Communications Holdings Inc. (LLL)

L-3 Communications Holdings, Inc., through its subsidiary, L-3 Communications Corporation, provides command, control, communications, intelligence, surveillance, and reconnaissance (C3ISR) systems; aircraft modernization and maintenance; and government services in the United States and internationally. Its C3ISR segment offers fleet management sustainment and support, such as procurement, systems integration, sensor development, modifications, and periodic depot maintenance for signals intelligence and communications intelligence systems; strategic and tactical signals intelligence systems; secure data links; secure terminal and communication network equipment and encryption management; and communication systems. The company?s Government Services segment provides communication software support, information technology services, and various engineering development services and integration support; engineering and information systems support services; teaching and training; h uman intelligence support services; command and control systems and software services; and technical and management services. Its Aircraft Modernization and Maintenance segment offers modernization and refurbishments, upgrades and sustainment, maintenance, and logistics support services, as well as turnkey aviation life cycle management services for military and various government and commercial customers. The company?s Electronic Systems segment provides components, products, subsystems, systems, and related services across various business areas, including power and control systems, electro-optic/infrared, microwave, simulation and training, precision engagement, warrior systems, security and detection, propulsion systems, avionics and displays, telemetry and advanced technology, undersea warfare, and marine services. L-3 Communications Holdings, Inc. was founded in 1997 and is based in New York, New York.

Advisors' Opinion:

• [By Rich Smith]

  Defense contractor L-3 Communications (NYSE: LLL  ) enjoyed a banner year for its stock in 2013, gaining 39% in 12 months of trading. But heading into its Thursday earnings report, things were looking pretty bleak for the company. Earnings for the year were expected to be only $8.30 or thereabouts, less than a 4% increase over 2012 levels, and probably too little growth to support the stock's 13-times earnings P/E ratio. But then the numbers came out, and a miracle happened:

• [By Marc Bastow]

  Command, control and communications leader L-3 Communications (LLL) raised its quarterly dividend 9% to 60 cents per share, payable March 17 to shareholders of record as of March 3.
  LLL Dividend Yield: 2.12%

• [By Garrett Cook]

  Technology sector was the top decliner in the market on Thursday. Top losers in the sector included QuickLogic (NASDAQ: QUIK), Glu Mobile (NASDAQ: GLUU), and L-3 Communications Holdings (NYSE: LLL).

• [By Rich Smith]

  The Department of Defense issued $1.3 billion worth of new contract awards Friday. However, a single, $950 million award for engineering services accounted for the bulk of the spending -- and that one went to a series of privately held companies. Publicly traded names fared less well. Among the few winners:

Top 5 Penny Stocks To Buy For 2014: Transocean Inc.(RIG)

Transocean Ltd. provides offshore contract drilling services for oil and gas wells worldwide. It offers deepwater and harsh environment drilling, oil and gas drilling management, and drilling engineering and drilling project management services. The company also offers well and logistics services. In addition, it engages in oil and gas exploration, development, and production activities primarily in the United States offshore Louisiana and Texas, and in the United Kingdom sector of the North Sea. As of February 10, 2011, the company owned, had partial ownership interests in, and operated 138 mobile offshore drilling units, including 47 high-specification floaters, 25 midwater floaters, 9 high-specification jackups, 54 standard jackups, and 3 other rigs, as well as 1 ultra-deepwater floater and 3 high-specification jackups under construction. Transocean Ltd. was founded in 1953 and is based in Zug, Switzerland.

Advisors' Opinion:

• [By Luke Jacobi]

  Transocean (NYSE: RIG) was also up, gaining 5.97 percent to $49.35 after the news that the company would be added to the S&P 500 hit the wires.

• [By Ben Levisohn]

  Shares of Seadrill have dropped 2.7% to $32.99 at 2:33 p.m. today, while Seadrill Partners has dipped 0.3% to $28.94 and Ship Finance International has fallen 2% to $16.86. Transocean (RIG), which has adopted something of a Seadrill model, has fallen 2.7% to $39.51.